EXCELS study results do not rule out potential cancer risk with omalizumab

J Allergy Clin Immunol. 2015 Jan;135(1):289. doi: 10.1016/j.jaci.2014.09.017. Epub 2014 Oct 29.

¹ Division of Epidemiology II, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md. Electronic address: jie.j.li@fda.hhs.gov.
² Division of Epidemiology II, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
³ Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.

No abstract available

Publication types